Becton, Dickinson (BDX) Beats On Q4 Earnings & Revenues
Zacks Investment Research | Nov 02, 2016 10:14PM ET
Becton, Dickinson and Company (NYSE:BDX) , popularly known as BD, reported fourth-quarter fiscal 2016 earnings of $2.12 per share, which beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter.
At comparable currency-neutral basis, revenues climbed 5.6% to $3.23 billion, marginally better than the Zacks Consensus Estimate of $3.22 billion.
Quarter Details
BD Medical revenues grew 7.9% year over year to almost $2.24 billion. The upside came from strong performance by Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units. Results were driven by double-digit growth in China, strength in dispensing and infusion, and sales of safety-engineered products.
BD Lifesciences revenues increased 2.1% from the year-ago quarter to $996 million. The upside came from Diagnostic Systems, Biosciences, research instruments and reagents in the U.S. This was partially offset by declines in Africa.
Geographically, U.S. revenues increased 6.7% to roughly $1.75 billion, while International revenues were up 5.2% on a currency-neutral basis to $1.48 billion.
Guidance
For fiscal 2017, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 4.5% to 5.0%.
Meanwhile, adjusted earnings (on a currency-neutral basis) are expected in the range of $9.62 to $9.72, reflecting year-over-year growth of 12.0% to 13.0%. However after including the estimated unfavorable impact from foreign currency, the company expects adjusted diluted earnings per share between $9.45 and $9.55, which represents growth of approximately 10.0% to 11.0%.
Zacks Rank & Key Picks
Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space are Intuitive Surgical Inc. (NASDAQ:ISRG) , AngioDynamics Inc. (NASDAQ:ANGO) and C.R. Bard (NYSE:BCR) .
Get The News You Want
Notably, Intuitive Surgical and AngioDynamics sport a Zacks Rank #1 (Strong Buy), while C.R. Bard has a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.